Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025Business Wire • 10/14/25
Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS NucleasesBusiness Wire • 10/09/25
Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B TrialBusiness Wire • 10/07/25
Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle SocietyBusiness Wire • 09/30/25
Precision BioSciences, Inc. (DTIL) Presents At H.C. Wainwright 27th Annual Global Investment Conference TranscriptSeeking Alpha • 09/16/25
Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure SymposiumBusiness Wire • 09/12/25
Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program StatusBusiness Wire • 09/08/25
Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/07/25
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire • 08/07/25
Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis BBusiness Wire • 08/06/25
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025Business Wire • 08/04/25
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular DystrophyBusiness Wire • 07/23/25
Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards ClinicBusiness Wire • 07/16/25
Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular DystrophyBusiness Wire • 06/25/25
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/15/25
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business UpdateBusiness Wire • 05/15/25
Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingBusiness Wire • 05/14/25
Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)Business Wire • 05/07/25
Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingBusiness Wire • 05/01/25
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock UpZacks Investment Research • 04/16/25
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis BBusiness Wire • 04/15/25
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare ConferenceBusiness Wire • 04/01/25
Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/26/25